AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
EAST RUTHERFORD, N.J., April 26, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2018 Earnings Conference Call | |
| When: | Thursday, May 3, 2018 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-877-260-1479 for U.S. |
| 1-334-323-0522 for International | |
| Passcode: 5093025 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 5093025 | |
| Available through Thursday, May 10, 2018 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
| Contact: | Stephanie LaFiura |
| Investor Relations Associate | |
| Tel: 201-804-3037 | |
| Email: [email protected] |
